Sudo Biosciences

Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Their lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain, a key mediator in cytokine signaling pathways linked to a broad range of immune-mediated inflammatory conditions. Founded in 2020 and headquartered in the United States, Sudo Biosciences recently received a significant $30.00M Series B investment on 13 February 2024. The investment saw participation from prominent investors such as TPG Capital, Dementia Discovery Fund, Leaps by Bayer, Monograph Capital, Sanofi Ventures, Velosity Capital, Eventide Asset Management, Frazier Life Sciences, UPMC Enterprises, and Surveyor Capital. With a focus on precision TYK2 therapeutics, Sudo Biosciences is poised to make substantial strides in the biopharma, biotechnology, and health care industries.